Bladder Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology

Citations Over TimeTop 1% of 2020 papers

Abstract

This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Bladder Cancer focuses on the clinical presentation and workup of suspected bladder cancer, treatment of non-muscle-invasive urothelial bladder cancer, and treatment of metastatic urothelial bladder cancer because important updates have recently been made to these sections. Some important updates include recommendations for optimal treatment of non-muscle-invasive bladder cancer in the event of a bacillus Calmette-Guérin (BCG) shortage and details about biomarker testing for advanced or metastatic disease. The systemic therapy recommendations for second-line or subsequent therapies have also been revised. Treatment and management of muscle-invasive, nonmetastatic disease is covered in the complete version of the NCCN Guidelines for Bladder Cancer available at NCCN.org. Additional topics covered in the complete version include treatment of nonurothelial histologies and recommendations for nonbladder urinary tract cancers such as upper tract urothelial carcinoma, urothelial carcinoma of the prostate, and primary carcinoma of the urethra.

Related Papers

• → Validation of a DNA Methylation-Mutation Urine Assay to Select Patients with Hematuria for Cystoscopy(2016)150 cited
• → The role of urine markers, white light cystoscopy and fluorescence cystoscopy in recurrence, progression and follow-up of non-muscle invasive bladder cancer(2013)36 cited
• → Photodynamic cystoscopy for bladder cancer diagnosis and for NMIBC follow-up: An overview of systematic reviews and meta-analyses(2023)4 cited
• → Early Recurrence of Non-Muscle Invasive Bladder Cancer as a Clinical Marker of a Poor Prognosis and Cancer-Specific Survival(2012)3 cited
• → Uromonitor ® as a novel sensitive and specific urine-based test for recurrence surveillance of patients with non-muscle invasive bladder cancer(2018)3 cited